Spots Global Cancer Trial Database for acute promyelocytic leukemia
Every month we try and update this database with for acute promyelocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AIDA 2000 Guidelines | NCT01064570 | Acute Promyeloc... | all-trans retin... | 1 Year - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | NCT03624270 | Acute Promyeloc... | Oral arsenic Tr... | 18 Years - | The University of Hong Kong | |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | NCT03624270 | Acute Promyeloc... | Oral arsenic Tr... | 18 Years - | The University of Hong Kong | |
| AIDA 2000 Guidelines | NCT01064570 | Acute Promyeloc... | all-trans retin... | 1 Year - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Optimum Induction Therapy of Low-risk APL | NCT05832320 | Acute Promyeloc... Induction Thera... Oral | Etoposide Daunorubicin | 18 Years - 75 Years | Peking University People's Hospital | |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | NCT03624270 | Acute Promyeloc... | Oral arsenic Tr... | 18 Years - | The University of Hong Kong | |
| Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia | NCT01910623 | Acute Promyeloc... | Health Related ... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy | NCT01472107 | Acute Promyeloc... Pregnancy | 18 Years - 50 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | NCT00985530 | Acute Promyeloc... | Tamibarotene Arsenic trioxid... | 18 Years - | Northwestern University | |
| A Safety Study of SGN-CD33A in AML Patients | NCT01902329 | Acute Myelogeno... Acute Myeloid L... Acute Promyeloc... | HMA SGN-CD33A | 18 Years - | Seagen Inc. | |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin | NCT00413166 | Acute Promyeloc... | All-Trans Retin... Arsenic Trioxid... Idarubicin Gemtuzumab Ozog... | - | M.D. Anderson Cancer Center | |
| Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | NCT00003861 | Leukemia Acute Lymphobla... Acute Promyeloc... | laboratory biom... | - | Alliance for Clinical Trials in Oncology | |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
| French Registry of First-line Treatment of Acute Promyelocytic Leukemia | NCT02938858 | Acute Promyeloc... | - 70 Years | Groupe Francophone des Myelodysplasies | ||
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | NCT01404949 | Acute Promyeloc... | Tretinoin and A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia | NCT02991066 | Acute Promyeloc... | 18 Years - | First Affiliated Hospital of Harbin Medical University | ||
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | NCT04996030 | Acute Promyeloc... | SY-2101 Arsenic Trioxid... | 18 Years - | Syros Pharmaceuticals | |
| AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | NCT00180128 | Leukemia, Promy... | all-trans retin... idarubicin mitoxantrone daunorubicin cytarabine | 16 Years - | Technische Universität Dresden | |
| Proteasome Inhibition in Acute Promyelocytic Leukemia | NCT01950611 | Relapsed Acute ... | Bortezomib | 1 Year - 75 Years | Christian Medical College, Vellore, India | |
| The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project | NCT04251754 | Acute Promyeloc... | - | The University of Hong Kong | ||
| A Safety Study of SGN-CD33A in AML Patients | NCT01902329 | Acute Myelogeno... Acute Myeloid L... Acute Promyeloc... | HMA SGN-CD33A | 18 Years - | Seagen Inc. | |
| "AIDA" Protocol (LAP 0493) | NCT01064557 | Leukemia | all-trans retin... | 1 Year - 75 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | NCT00003861 | Leukemia Acute Lymphobla... Acute Promyeloc... | laboratory biom... | - | Alliance for Clinical Trials in Oncology | |
| Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia | NCT00517712 | Acute Promyeloc... | Single agent ar... | - | Christian Medical College, Vellore, India | |
| Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia | NCT03751917 | Acute Promyeloc... | Arsenic Trioxid... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | NCT01226303 | Acute Promyeloc... | ATRA ATRA + IDA | - 21 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | NCT01987297 | Acute Promyeloc... | ATRA+Arsenic ATRA+Chemo | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | NCT01987297 | Acute Promyeloc... | ATRA+Arsenic ATRA+Chemo | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | NCT00504764 | Acute Promyeloc... | Arsenic Trioxid... Autologous Tran... Allogenic Trans... ATRA | 18 Years - | PETHEMA Foundation | |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
| Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL | NCT00520208 | Acute Promyeloc... | Tamibarotene | 18 Years - | CytRx | |
| Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | NCT00408278 | Acute Promyeloc... | ATRA Idarubicina Mitoxantrone ARA-C | - 75 Years | PETHEMA Foundation | |
| Proteasome Inhibition in Acute Promyelocytic Leukemia | NCT01950611 | Relapsed Acute ... | Bortezomib | 1 Year - 75 Years | Christian Medical College, Vellore, India | |
| ASCT for Relapsed APL After Molecular Remission | NCT00907582 | Acute Promyeloc... Relapse | autologous hema... | 18 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | NCT01226303 | Acute Promyeloc... | ATRA ATRA + IDA | - 21 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Frontline Oral Arsenic Trioxide for APL | NCT04687176 | Acute Promyeloc... | Oral Arsenic Tr... | - | The University of Hong Kong | |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | NCT01404949 | Acute Promyeloc... | Tretinoin and A... | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
